Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ensartinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 0 results

Early research (Phase 1)UnknownNCT03804541
What this trial is testing

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

Who this might be right for
ALK-POSITIVE NSCLC
Betta Pharmaceuticals Co., Ltd. 6
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06779539
What this trial is testing

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
West China Hospital 33
Early research (Phase 1)Study completedNCT02959619
What this trial is testing

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Who this might be right for
Solid TumorNon-Small Cell Lung Cancer Metastatic
Betta Pharmaceuticals Co., Ltd. 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06780839
What this trial is testing

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

Who this might be right for
NSCLC, Stage I, II, IIIA, IIIB
Peking University Cancer Hospital & Institute 70
Large-scale testing (Phase 3)Active Not RecruitingNCT02767804
What this trial is testing

EXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Xcovery Holdings, Inc. 290
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06772610
What this trial is testing

The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors

Who this might be right for
NSCLCALKStage I+1 more
Shanghai Pulmonary Hospital, Shanghai, China 40
Not applicableLooking for participantsNCT05498064
What this trial is testing

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase I1171NEnsartinib
Peking Union Medical College Hospital 490
Testing effectiveness (Phase 2)Looking for participantsNCT07448116
What this trial is testing

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Advanced Tumor
Betta Pharmaceuticals Co., Ltd. 164
Early research (Phase 1)Study completedNCT03536481
What this trial is testing

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Who this might be right for
Lung Cancer
Betta Pharmaceuticals Co., Ltd. 74
Testing effectiveness (Phase 2)Study completedNCT01625234
What this trial is testing

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Who this might be right for
Advanced Solid TumorsNon-small Cell Lung Cancer
Xcovery Holdings, Inc. 131
Testing effectiveness (Phase 2)UnknownNCT05178511
What this trial is testing

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

Who this might be right for
The Diagnosis Was ALK Positive NSCLCSecond Generation ALK-TKI is ResistantEfficacy of Ensatinib in This Subset of Patients
Li Zhang, MD 40